SOLICITATION NOTICE
Q -- Conduct mutation testing in RB1
- Notice Date
- 7/20/2012
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120121-MD
- Archive Date
- 8/18/2012
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS) plans to procure on a sole source basis with Solutions by Sequence of 399 Bathwurst St Toronto, ON M5T 2S8, Canada to conduct mutation testing of the RB1 gene. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 621511 and the business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance shall be twelve (12) months from date of award. It has been determined that there is no opportunity to acquire green products or services under this procurement. Retinoblastoma (RB) is a rare childhood cancer that has contributed enormously to our basic understanding of carcinogenesis. Four decades ago, Alfred Knudson developed his hypothesis of tumor suppressor genes based on the inheritance of retinoblastoma within families. With the discovery of the RB1 gene it became possible to evaluate mutation-specific outcomes, but these studies have been limited because of the difficulty of mutation testing in this large 27-exon gene and the rarity of the cancer. NCI shall evaluate the genotype-phenotype associations among a cohort of retinoblastoma survivors, many of whom have heritable retinoblastoma and some of whom have developed second tumors, either malignant or benign. Since RB1 was identified as the gene for retinoblastoma, two other tumor suppressor genes of major interest, P53 and CDKN2A have been identified as major susceptibility genes for Li-Fraumeni syndrome and familial melanoma. Both of these genes are in pathways closely related to RB1, and the tumors associated with mutations in these genes (bone and soft tissue sarcomas and melanoma) are the most frequent second cancers after heritable retinoblastoma in this cohort. It is plausible that location-specific mutations in RB1 could predict risk of sarcomas or melanomas following heritable RB. The purpose of this contract is to provide high quality mutation testing for highly characterized individuals with retinoblastoma and second tumors. These 45 samples are unique; many of the individuals are now deceased and it is imperative to have the highest quality testing possible, since these samples are irreplaceable. Mutation testing for the RB1 gene is a highly technological challenge. Standardized handling of the DNA and reagents is crucial for accurate determination of the mutations. There is no other facility with comparable experience in the world and no other facility that focuses exclusively on RB1 mutation detection. Over the years, Solutions by Sequence has perfected the technology and is currently the world's preeminent laboratory for this diagnostic test. They also have the highest rates of mutation detection (approximately 95% for bilateral cases and 93% for unilateral familial) and are capable of handling a large number of samples. For these extremely precious, irreplaceable samples, it is the only responsible source for this requirement. In addition, Solutions by Sequence has completed mutation testing on the majority of NCI's other samples. Having Solutions by Sequence conduct the additional testing that NCI now requires will ensure consistency with the previous results. For the aforementioned reasons, Solutions by Sequence is the only known lab that NCI can use to achieve its primary study aims. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 03, 2012. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120121-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120121-MD/listing.html)
- Record
- SN02810346-W 20120722/120720235420-32e9e6184416b73d30d9c9ab0c93f8ba (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |